SCHEMBL12011007

SCHEMBL12011007

O=C(Nc1ccccc1)Nc1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.69
CA1 P00915 5/20 0.69
CA2 P00918 5/20 0.69
CA9 Q16790 5/20 0.69
TP53 P04637 2/20 0.63
EPHX1 P07099 1/20 0.63
TSHR P16473 1/20 0.63
EPHX2 P34913 1/20 0.63
CDK9 P50750 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
CLK4 Q9HAZ1 1/20 0.63
CASP3 P42574 1/20 0.60
SENP7 Q9BQF6 1/20 0.60
MAOA P21397 2/20 0.58
MAOB P27338 2/20 0.58
KMT2A Q03164 3/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 2/20 0.56
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diphenylurea SCHEMBL28392913 0.86 SMN1; SMN2 (0.77) CA12CA1CA2CA9TP53
SCHEMBL9913185 0.85 CA12 (0.73) CA12CA1CA2CA9TP53
SCHEMBL3460960 0.83 CA12 (0.71) CA12CA1CA2CA9TP53
SCHEMBL12010905 0.83 CA12 (0.71) CA12CA1CA2CA9TP53
SCHEMBL8247039 0.82 ALDH1A1 (0.48) CA12CA1CA2CA9KMT2A
SCHEMBL19857281 0.82 ALDH1A1 (0.66) CA12CA1CA2CA9TP53
SCHEMBL3680148 0.82 PRMT1 (0.75) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL11059378 0.82 SMN1; SMN2 (0.94) CA12CA1CA2CA9TP53
SCHEMBL12870246 0.81 CA12 (0.69) CA12CA1CA2CA9TP53
SCHEMBL4969968 0.81 KMT2A (0.69) CA12CA1CA2CA9TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343963-B2 Sulfamoyl-phenyl-ureido compounds and their use as medicament 4SC AG (DE) 2013-01-01 US disclosed
US-8252841-B2 Methods of inhibiting bacterial virulence and compounds relating thereto THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-08-28 US disclosed
US-8252841-B2 Methods of inhibiting bacterial virulence and compounds relating thereto THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-08-28 US disclosed
WO-2010086177-A1 SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS 4SC AG (DE) 2010-08-05 WO disclosed
US-20100197640-A1 NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT 4SC AG (DE) 2010-08-05 US disclosed
US-20100048573-A1 Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2010-02-25 US disclosed
US-20100048573-A1 Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2010-02-25 US disclosed
WO-2009088549-A2 METHODS OF INHIBITING BACTERIAL VIRULENCE AND COMPOUNDS RELATING THERETO THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-07-16 WO disclosed
US-7317030-B2 Compounds as inhibitors of cell proliferation and viral infections 4SC AG (DE) 2008-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197640-A1 NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT SLC14A1, UTS2R, UROD CA12 4158/4885CA1 4272/4885CA2 2340/4885
US-20100048573-A1 Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto MMP8, SLC11A2, NFKBIA CA12 4360/4885CA1 4431/4885CA2 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.